Compass Therapeutics, Inc. (CMPX)

Compass Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	12.42	12.24	11.66	10.93	12.91	11.6
Research & Development	41	38.12	30	70.96	14.9	22.45
Other Operating Expenses	0	0	0	0	1.66	0
Operating Expenses	53.43	50.36	41.66	81.88	29.47	34.05
Operating Income	-53.43	-50.36	-41.66	-81.88	-29.47	-34.05
Interest Expense / Income	0	0	0	0	0	1.23
Other Expense / Income	-7.98	-7.87	-2.43	0.3	-	-0.63
Pretax Income	-45.44	-42.49	-39.23	-82.18	-29.47	-34.65
Income Tax	0	0	0	0	0.03	0.09
Net Income	-45.44	-42.49	-39.23	-82.18	-29.5	-34.74
Shares Outstanding (Basic)	137	127	105	63	31	7
Shares Outstanding (Diluted)	137	127	105	63	31	7
Shares Change	8.10%	20.76%	67.31%	104.28%	359.96%	-
EPS (Basic)	-0.35	-0.33	-0.37	-1.31	-0.96	-5.19
EPS (Diluted)	-0.35	-0.33	-0.37	-1.31	-0.96	-5.19
Free Cash Flow	-42.31	-40.65	-34.16	-21.12	-26.77	-32.21
Free Cash Flow Per Share	-0.31	-0.32	-0.33	-0.34	-0.87	-4.81
EBITDA	-43.57	-40.6	-37.32	-80.56	-27.06	-31.31
Depreciation & Amortization	1.87	1.89	1.9	1.62	2.4	2.12
EBIT	-45.44	-42.49	-39.23	-82.18	-29.47	-33.43

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).